Literature DB >> 16632914

Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.

Shuzo Usuku1, Yuzo Noguchi, Mitsuo Sakamoto, Takuya Adachi, Hiroko Sagara, Koji Sudo, Masako Nishizawa, Makiko Kondo, Osamu Tochikubo, Mitsunobu Imai.   

Abstract

Drug-resistance genotypes were investigated in a patient under treatment with anti-HIV drugs. Since the drug resistance-associated mutations in plasma HIV-1 RNA and proviral DNA in peripheral blood mononuclear cells (PBMCs) were inconsistent, changes were followed over time, and the discrepancy was shown to persist for a long period. In plasma HIV-1 RNA, D67N, K70R, T215Y, and Y188L were present in the reverse transcriptase (RT) region, and two primary mutations, I84V and L90M, were noted in the protease (Pro) region. In contrast, in proviral DNA, no drug resistance-associated mutations were found in the RT region, and mutations such as L90L/M were only infrequently present in the Pro region. This situation persisted for more than 3 years. In addition, sequencing analysis of the V3 loop in the envelope gene showed that non-syncytium-inducing/macrophage-tropic viruses contribute to acquisition of drug resistance. In this study, drug-resistant viruses were produced primarily at macrophages, and drug-sensitive viruses were maintained in PBMCs as a reservoir.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632914

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  2 in total

1.  Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country.

Authors:  Karidia Diallo; Wendy E Murillo; Ivette Lorenzana de Rivera; Jan Albert; Zhiyong Zhou; John Nkengasong; Guoqing Zhang; Jennifer F Sabatier; Chunfu Yang
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-28

2.  Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment.

Authors:  Kristen E Ellis; George T Nawas; Connie Chan; Lawrence York; Julia Fisher; Elizabeth Connick; Tirdad T Zangeneh
Journal:  Open Forum Infect Dis       Date:  2019-12-14       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.